Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Acute Myeloid Leukemia AML

615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation I

Watch Session

588 Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Paola Minetto, Anna Candoni, Fabio Guolo, et al.

 

589 Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, et al.

 

590 Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

Danielle Hammond, Sanam Loghavi, Marina Konopleva, et al.

 

591 Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Andrew H Wei, Glen A Kennedy, Kirk L Morris, et al.

 

592 Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

Xinxin Cao, Ming-hui Duan, Ai-lin Zhao, et al.

 

593 Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children’s Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, Chad A. Hudson, Todd A. Alonzo, et al.